Use this URL to cite or link to this record in EThOS:
Title: Epstein-Barr virus in the pathogenesis of post-transpant lymphoproliferative disease
Author: Burns, David Meriton
ISNI:       0000 0004 5351 7580
Awarding Body: University of Birmingham
Current Institution: University of Birmingham
Date of Award: 2015
Availability of Full Text:
Access from EThOS:
Access from Institution:
Post-transplant lymphoproliferative disease (PTLD) is a life threatening complication of transplantation, often associated with the B-lymphotrophic Epstein-Barr virus (EBV). In order to further our understanding of the relationship between EBV infection and PTLD, a series of clinical and laboratory studies were undertaken. A multicentre United Kingdom study defined current outcomes and prognostic factors for patients with PTLD arising after solid organ transplant. A study to define incidence and risk factors for EBV reactivation and PTLD amongst patients undergoing allogeneic haematopoietic stem cell transplant (allo-HSCT) revealed greatly reduced risk amongst patients with Non-Hodgkin lymphoma previously treated with Rituximab. Complementary laboratory studies to explore the pathophysiology of EBV reactivation after allo-HSCT demonstrated that the virus maintains selectivity for, and can drive the expansion of, circulating CD27+ memory B-cells; these are normally scarce for many months after transplant. Investigations were also performed to examine the role of cell survival, DNA damage signalling and mutations as possible drivers of clonal selection in EBV-infected B-cell cultures, as an \(in\) \(vitro\) model for PTLD. Finally, work was undertaken to characterise EBV-epitope specific T-cell responses expanding in patients successfully treated with donor lymphocyte infusion for Rituximab-refractory PTLD arising after allo-HSCT.
Supervisor: Not available Sponsor: Not available
Qualification Name: Thesis (Ph.D.) Qualification Level: Doctoral
EThOS ID:  DOI: Not available
Keywords: RC Internal medicine